Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.

被引：0
|
作者：
Anton, A
Puertolas, T
Ramos, M
Barnadas, A
Florian, J
Grande, R
Ribelles, N
Lomas, M
机构：
[1] Hosp Miguel Servet, Zaragoza, Spain
[2] Ctr Oncol, Coruna, Spain
[3] Hosp Germans Trias & Pujol, Badalona, Spain
[4] Hosp Barbastro, Huesca, Spain
[5] Hosp Virgen Victoria, Malaga, Spain
[6] Hosp Infanta Cristina, Badajoz, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
751
引用
收藏
页码：64S / 64S
页数：1
相关论文
共 50 条
  • [31] Phase III study of gemcitabine plus vinorelbine (VG) versus vinorelbine (V) in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracyclines (A) and taxanes (T).: Final results of GEICAM 2000-04 study.
    Muñoz, M.
    Martin, M.
    Ruiz, A.
    Balil, A.
    García-Mata, J.
    Calvo, L.
    Jara, C.
    Alba, E.
    Salas, F.
    Soto, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 21S - 21S
  • [32] MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE
    Ozguroglu, M.
    Mansutti, M.
    Kerr, R.
    Awada, A.
    Rha, S. Y.
    Im, Y. H.
    Perez Manga, G.
    Germann, N.
    Fumoleau, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 69 - 69
  • [33] Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Possinger, K
    Schippinger, W
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Papke, J
    Freier, W
    de Velde, HV
    Schmid, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [34] A phase II pilot study of vinorelbine and cisplatin in patients with metastatic breast cancer (MBC)
    Abraham, J
    McAdam, K
    Wilson, CB
    Earl, HM
    BRITISH JOURNAL OF CANCER, 2001, 85 : 51 - 51
  • [35] Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.
    Koutras, Angelos
    Zagouri, Flora
    Koliou, Georgia-Angeliki
    Lazaridis, Georgios
    Tryfonopoulos, Dimitrios
    Kotsakis, Athanasios
    Res, Eleni
    Kentepozidis, Nikolaos K.
    Razis, Evangelia
    Psyrri, Amanda
    Koumakis, Georgios
    Kalofonos, Haralabos
    Fountzilas, George
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Benekli, Mustafa
    Yildiz, Ramazan
    Uner, Aytug
    Er, Ozlem
    Yamac, Deniz
    Alkis, Necati
    Coskun, Ugur
    Camci, Celalettin
    Buyukberber, Suleyman
    ONCOLOGY, 2007, 72 (5-6) : 308 - 313
  • [37] SAFETY AND EFFICACY OF VINORELBINE PLUS LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES
    Kudo, S.
    Makino, T.
    Hasunuma, A.
    Ahiko, Y.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Cisplatin-vinorelbine as first line chemotherapy in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes: Results of a retrospective analysis
    Raafat, J.
    Mourad, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S182
  • [39] Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
    Schaller, G
    Bangemann, N
    Gonsch, T
    Weber, J
    Kleine-Tebbe, A
    Conrad, B
    Klare, P
    Hindenburg, HJ
    Ruhmland, B
    Lakner, V
    Hinke, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S95
  • [40] Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
    Martin, Miguel
    Ruiz, Amparo
    Munoz, Monserrat
    Balil, Ana
    Garcia-Mata, Jesus
    Calvo, Lourdes
    Carrasco, Eva
    Mahillo, Esther
    Casado, Antonio
    Angel Garcia-Saenz, Jose
    Jose Escudero, M.
    Guillem, Vicente
    Jara, Carlos
    Ribelles, Nuria
    Salas, Fernando
    Soto, Celia
    Morales-Vasquez, Flavia
    Rodriguez, Cesar A.
    Adrover, Encarna
    Ramon Mel, Jose
    LANCET ONCOLOGY, 2007, 8 (03): : 219 - 225
12345